These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38111255)

  • 1. Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics.
    Nakai H; Matsumura N
    Expert Opin Pharmacother; 2023; 24(18):2161-2173. PubMed ID: 38111255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
    Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
    N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    Paik J
    Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 6. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
    Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    Smith M; Pothuri B
    Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
    Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latest clinical evidence of maintenance therapy in ovarian cancer.
    Walsh CS
    Curr Opin Obstet Gynecol; 2020 Feb; 32(1):15-21. PubMed ID: 31833941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
    Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line PARP inhibitors in ovarian cancer: summary of an
    Banerjee S; Gonzalez-Martin A; Harter P; Lorusso D; Moore KN; Oaknin A; Ray-Coquard I
    ESMO Open; 2020 Nov; 5(6):e001110. PubMed ID: 33310779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
    Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
    Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
    Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
    Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs.
    Nakai H; Matsumura N
    Int J Clin Oncol; 2022 Jun; 27(6):1001-1012. PubMed ID: 35416600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
    Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
    Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The forefront of ovarian cancer therapy: update on PARP inhibitors.
    Mirza MR; Coleman RL; González-Martín A; Moore KN; Colombo N; Ray-Coquard I; Pignata S
    Ann Oncol; 2020 Sep; 31(9):1148-1159. PubMed ID: 32569725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer.
    Nakamura K; Matsuoka H; Yorimitsu M; Ogawa M; Kanemori M; Sueoka K; Kozai A; Nakamura H; Haruma T; Shiroyama Y; Hayata Y; Sugii H; Ueda A; Kurihara S; Urayama S; Shimizu M; Masuyama H
    Jpn J Clin Oncol; 2024 Jan; 54(1):31-37. PubMed ID: 37721176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
    Sghaier S; Corbaux P; Ray-Coquard I; Lim MC; Hasegawa K; Nieuwenhuysen EV; Gonzalez A; Raspagliesi F; Freyer G
    Future Oncol; 2023 Aug; 19(25):1715-1727. PubMed ID: 37650734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.